Acute urinary retention as a complication of primary varicella-zoster infection of childhood – a second reported case by Favara, David M & Levy, Maurice
196 April 2012, Vol. 102, No. 4  SAMJ
Correspondence
Acute urinary retention as a 
complication of primary varicella-
zoster infection of childhood –  
a second reported case
To the Editor: We discuss the case of a child with acute urinary 
retention and constipation following primary varicella-zoster 
infection (chickenpox). To our knowledge, this unusual complication 
has only been reported once before.1 
An 8-year-old boy presented 2 days after developing urinary 
retention. Chickenpox had been diagnosed 2 weeks previously and 
treated with paracetamol and topical calamine lotion. There was no 
similar preceding history, trauma, use of anti-cholinergic medication, 
or other urinary or neurological signs or symptoms. The child was 
HIV-negative. He was fully ambulant, well hydrated and apyrexial. 
His urinary bladder was abdominally palpable and was catheterised 
at the referring hospital, draining clear urine. The trunk and 
extremities had healing primary varicella-zoster (chickenpox) skin 
lesions. No evidence of sacral or perineal shingles rash (secondary 
varicella-zoster infection) or neurological deficit was found. Urine 
dipstix, renal function tests, blood electrolytes, full blood count and 
C-reactive protein were normal. Lumbar puncture and serology for 
varicella-zoster virus were not done.
After excluding urethral and bladder outlet obstruction, anti-
cholinergic use, urinary tract or bladder infection and transverse 
myelitis, primary varicella-zoster virus-related urinary retention and 
constipation was tentatively diagnosed. He was admitted and given 
oral acyclovir (400 mg 8-hourly for 10 days) and laxatives. After 3 
doses of acyclovir, the catheter was temporarily removed and the 
child gradually began to urinate and resumed passing stools. There 
were no further similar complaints after discharge. Informed consent 
for publication was obtained from the patient.
The varicella-zoster virus is an exclusively human virus belonging 
to the Alphaherpesvirinae subfamily of the Herpesviridae.2 It is 
neurotropic and very contagious, and is spread mostly by virus-
filled respiratory droplets and, to a lesser degree, from skin lesions.3 
Varicella-zoster causes 2 distinct clinical syndromes: chickenpox/
varicella, the initial or primary infection of the host; and shingles/
zoster, corresponding to reactivation of latent infection.2
In healthy children, chickenpox usually has no prodrome, is 
self-limiting, and is characterised by a distinct pruritic exanthum 
(macules progressing to papules and virus-rich vesicles before 
crusting), malaise and low-grade fever. Treatment is symptomatic.
Once the self-limiting initial infection is contained by the immune 
system, the virus establishes itself within the spinal cord ganglia 
(dorsal root/sensory ganglia being the most common site) and 
becomes latent. Transport to the ganglia is thought to be via 
retrograde axonal transport (from the skin) and via haematogenous 
spread.2
Re-activation of dormant varicella-zoster virus occurs when cell-
mediated immunity is weakened, allowing viral replication within the 
infected ganglia. Viral spread along the nerves associated with the 
affected ganglia causes symptoms associated with nerve dysfunction.3 
Re-activation within sensory ganglia results in a painful dermatomal 
zoster rash whereas signs of re-activation within the autonomic 
sacral ganglia include urinary retention, zoster cystitis, or ano-
rectal dysfunction.2-4 We found 1 report in the English literature of 
urinary retention complicating primary varicella-zoster infection.1 
Their case differed in having a large primary varicella-zoster vesicle 
on the glans penis obstructing the urethral meatus.1 Incision and 
removal of the vesicle did not resolve the retention, necessitating 
suprapubic catheterisation and dilatation of a meatal stricture, with 
gradual regaining of full micturition control. The authors speculated 
that the retention was due to combined neurogenic effects of the 
primary varicella-zoster infection on the sacral ganglia (i.e. the virus 
establishing itself within the sacral ganglia before becoming latent) 
and obstruction caused by the vesicle and stricture.1
Having excluded other pathology, we believe that our patient’s 
presentation was congruent with the hypothesis that, towards the 
end of primary varicella-zoster infection, virus infecting a specific 
ganglion (prior to becoming latent) may cause transient neurological 
effects. As this was the patient’s first varicella-zoster infection, 
we believe that, should infection be re-activated (by old age or 
immune suppression), he may again develop urinary dysfunction 
and constipation.
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Responding to the evidence for 
improved treatment for cryptococcal 
meningitis in resource-limited settings
To the Editor: The World Health Organization (WHO) issued the 
first evidence-based treatment guidelines for cryptococcal meningitis 
in December 2011.1 Although its incidence has decreased with 
increased access to antiretroviral therapy, cryptococcal meningitis 
remains a major cause of death in people with HIV/AIDS, with 
over 500 000 deaths every year in sub-Saharan Africa. It is a leading 
cause of death in the Médecins sans Frontières (MSF) HIV/AIDS 
programmes in Africa.2,3 
The preferred treatment in the WHO guidelines combines 
amphotericin B injectable with oral solid formulations of either 
flucytosine or fluconazole. The liposomal injectable form of 
amphotericin B is also indicated as an alternative to conventional 
amphotericin B because it is associated with fewer side-effects. 
However, it is acknowledged that this option is currently too 
expensive for routine use in most countries.1
Access to fluconazole was a major concern a decade ago, with 
100-fold price differences reported in developing countries with the 
similar gross domestic product.4 In South Africa, the drug became an 
early symbol of the struggle to improve access to affordable treatment 
for people living with HIV/AIDS. In early 2000 the Treatment 
Action Campaign imported generic versions of fluconazole from 
Thailand, in defiance of patent laws at the time. Fluconazole is 
generally available today, with quality-assured generics costing as 
little as US$0.07 per 200 mg capsule.5 However, access to the preferred 
drugs, amphotericin B and flucytosine, is a challenge, as highlighted 
by a rapid survey of MSF HIV/AIDS programmes in 9 countries. 
Amphotericin B was available in only 4 countries, and cost between 
US$70 and $170 per patient for a 2-week induction treatment. Data 
on the registration status, availability and price of flucytosine and 
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amphotericine B in 9 African countries is available at http://tinyurl.
com/857zxdf.
MSF uses amphotericin B in its HIV/AIDS projects, but national 
availability is poor. For instance, although the drug is registered 
in Ethiopia and the Democratic Republic of the Congo, it is not 
available. Access to flucytosine is even more problematic; it was not 
registered in the 9 countries surveyed and was only available in South 
Africa under legislation for special prescription at US$252 per patient 
for a 2-week induction treatment. 
The development of guidelines for the treatment of cryptococcal 
meningitis and other opportunistic infections is an important advance. 
The WHO should be congratulated for commissioning a thorough 
review of the evidence and recommending treatment options based 
on the patients’ best interests, not simply on what is available. 
The urgent challenge ahe ad for all involved in translating these 
guidelines into practice is to accelerate access to affordable treatment 
by supporting the registration and procurement of flucytosine and 
amphotericin B at affordable prices in all the countries where these 
drugs are needed. 
We thank all MSF staff who co-operated in providing registration, 
availability and price data.
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Sequel: Chris Barnard and the 
Hunterian Museum
To the Editor: On 1 September 2007, I wrote to the Journal regarding 
one’s puzzlement that in the Hunterian Museum at the Royal College 
of Surgeons of England, London, no mention was made of the 
surgeon who performed the first heart transplant, or of where the 
operation took place.
I had the privilege and pleasure of meeting Sir Terence English at 
a wedding last year. He was born and educated in South Africa and – 
12 years after Barnard’s achievement – performed the first successful 
heart transplant in the UK. He directed the British Heart Foundation 
Heart Transplant Unit, served as President of the Royal College of 
Surgeons, and was knighted in 1991.
We discussed the anomaly; he agreed that it was a serious one, and 
undertook to attend to the exclusion. Recently, he e-mailed as follows: 
‘After discussions with the new Curator of the Hunterian Museum 
the omission of Chris Barnard’s name has been corrected. The new 
display now starts: “In December 1967 Christiaan Barnard performed 
the first human heart transplant in Cape Town, South Africa. The 
patient, Louis Washkansky, lived for 18 days. A month later Barnard 
transplanted a second patient who lived for nearly two years. Norman 
Shumway at Stanford …’’’
I am very grateful to Sir Terence, and I know that other South 
African doctors will share this appreciation.
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